Management View "We continue to make steady progress in our TakeAim Lymphoma study in primary CNS lymphoma" and said the TakeAi ...

Thank you, and welcome to the Curis First Quarter 2026 Business Update Call. Before we begin, I'd like to encourag ...

Curis Inc (CRIS) reports advancements in cancer studies and financial hurdles, with a focus on future growth and strategic developments.

The FDA has freed Curis from a remaining partial clinical hold, lifting the pause on a phase 1/2 leukemia study and giving the green light to launch using the recommended phase 2 dose. In April 2022, ...

Cancer drug specialist Curis (NASDAQ: CRIS) had a Friday to forget. The biotech's share price took a nearly 37% hit after the company reported some disquieting news about a leading pipeline drug.

The list of biotechs under clinical hold keeps getting longer. Curis is the latest company to join the list, with the FDA slapping a partial hold on a phase 1/2a leukemia study while it gathers ...

A Curis clinical trial under a partial FDA hold for more than a year is now cleared to resume, and the biotech is working with clinical sites to enroll patients whose blood cancers exhibits certain ...

Curis CRIS will release its quarterly earnings report on Tuesday, 2025-05-06. Here's a brief overview for investors ahead of the announcement. Analysts anticipate Curis to report an earnings per share ...

What a difference a day makes. Following a serious pop for its stock on Wednesday, given very encouraging news about one of its pipeline drugs, Curis (NASDAQ: CRIS) saw its shares dive by almost 20% ...

Curis (CRIS 1.98%), a small-cap cancer specialist, posted a healthy gain in August. The biotech's shares rose by 16.6% last month, according to data provided by S&P Global Market Intelligence. What ...